Tavaborole (AN2690, trade name Kerydin) is a topical antifungal medication for the treatment of onychomycosis, a fungal infection of the nail and nail bed. Tavaborole began its Phase 3 trials in December 2010 and was approved in July 2014. Tavaborole inhibits an essential fungal enzyme, leucyl-tRNA synthetase, that is required for protein synthesis. The inhibition of protein synthesis leads to termination of cell growth and then cell death, eliminating the fungal infection.

CAS：174671-46-6
中文别名：
英文别名：5-fluoro-1,3-dihydro-1-hydroxy-2,1-benzoxaborole;onychomycosis;Tavaborole (USAN);UNII-K124A4EUQ3;5-fluoro-1-hydroxy-3H-2,1-benzoxaborole;5-fluoro-1,3-dihydro-2,1-benzoxaborol-1-ol;2,1-Benzoxaborole,5-fluoro-1,3-dihydro-1-hydroxy;Tavaborole;1,3-dihydro-5-fluoro-1-hydroxy-2,1-benzoxaborole;5-fluoro-3H-benzo[c][1,2]oxaborol-1-ol;AN 2690;5-fluorobenzo[c][1,2]oxaborol-1(3H)-ol;
分子式：C7H6BFO2
分子量：151.931
精确质量：152.044
Psa：29.46
Logp：0.0434

UNII：K124A4EUQ3

密度：1.288 g/cm3
沸点：230.831ºC at 760 mmHg
闪点：93.404ºC